To further develop gene therapy for patients with glioblastomas, an experimental gene therapy protocol was established comprising a series of imaging parameters for (i) noninvasive assessment of viable target tissue followed by (ii) targeted application of herpes simplex virus type 1 (HSV-1) amplicon vectors and (iii) quantification of treatment effects by imaging. We show that viable target tissue amenable for application of gene therapy vectors can be identified by multitracer positron emission tomography (PET) using 2-18
Introduction
Gliomas are the most common primary intracranial neoplasms, and f50% of all gliomas are glioblastomas, the most fatal primary brain neoplasm (1, 2) . In view of the high incidence (10-15 per 100,000) and poor prognosis of malignant brain tumors treated with conventional therapies, such as surgery, chemotherapy, brachytherapy, and radiotherapy (3), research focusing on the development of clinically effective alternative therapies such as gene therapy is of utmost importance. Localized transduction of brain tumor cells with therapeutic genes may influence their biological properties by rendering them sensitive to prodrugs, altering the expression of cell cycle regulating proteins, inhibiting angiogenesis, stimulating the immune response, or triggering apoptosis. The helper virus-free herpes simplex virus type 1 (HSV-1) amplicon has been shown to be a safe and efficient vector system in culture and in vivo to transduce various central nervous system (CNS)-derived cells including human gliomas (4) (5) (6) (7) (8) .
Clinical studies revealed that a gene therapy approach as an adjuvant to the surgical resection of recurrent high-grade gliomas can be done safely, although clinical responses were observed in only a few patients with small brain tumors (9) (10) (11) (12) (13) (14) . The lack of therapeutic efficiency of replication-deficient vector systems in clinical settings may be due to insufficient distribution of vector particles throughout the tumor and heterogeneity of tumor tissue with ineffective transduction of proliferating tumor cells. Therefore, further development of clinically valuable gene therapy protocols for use in patients is an important but also a challenging issue, according to experience. To address these challenges, it is important to develop assays that allow (i) a noninvasive determination of viable target tissue, which might benefit from a biological treatment paradigm, such as gene therapy, as well as assays (ii) for the assessment of the transduced ''tissue dose'' of a therapeutic gene in patients in vivo. Therefore, one important issue for making gene therapy applicable to patients with brain tumors is the establishment of gene therapy protocols, which contain molecular imaging technology including the assessment of endogenous gene expression as marker for viable and proliferating tumor and the noninvasive monitoring of the location, magnitude, and duration of vector-mediated gene expression in vivo (7, 15, 16) . Previously, we and others have shown the in vivo functionality of various gene coexpression constructs based on the internal ribosome entry site (IRES) element serving for the proportional coexpression of a marker gene that can be imaged and a proportionally coexpressed therapeutic gene (7, 17, 18) . In the present study, we are using a vector proportionally coexpressing Escherichia coli cytosine deaminase (cd) as therapeutic gene, HSV-1-tk39 as positron emission tomography (PET) marker as well as therapeutic gene, and green fluorescent protein gene (gfp) fused to HSV-1-tk39 (19) as cell culture marker gene. The combination of the transgenes cd and HSV-1-tk39, which encode prodrug-activating enzymes, serves synergistic antitumor activity (20) . We show that (i) identification of target tissue, (ii) imaging-guided vector application, (iii) determination of the tissue dose of vector-mediated gene expression, and (iv) correlation to the induced therapeutic effect are feasible.
Materials and Methods
Cells. Rat F98 and RG2 glioma cells, human Gli36dEGFR glioma cells (kind gift of Dr. David Louis, Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Boston, MA), and human U87dEGFR glioma cells (kind gift of Dr. H-J. Su Huang, Ludwig Institute for Cancer Research, San Diego, CA) were grown as monolayers in DMEM (Life Technologies, Karlsruhe, Germany) supplemented with 10% fetal bovine serum (Roche Diagnostics, Mannheim, Germany) and 100 units/mL penicillin and 100 Ag/mL streptomycin (Life Technologies) at 37jC in a 5% CO 2 /95% air atmosphere.
HSV-1 amplicon vector. The HSV-1 amplicon backbone pHSV-GN (kind gift of Dr. Xandra Breakefield, Neurogenetics Unit, Massachusetts General Hospital, Boston, MA; refs. 4, 5) was used to create the coexpression cassette containing cd, tk39, and gfp genes as previously described (7) . Amplicon plasmid was packaged helper virus-free as previously described to generate HSV-1-cdIREStk39gfp amplicon vector (HSV-CITG; ref. 7) . Purified vector stocks were titrated (transducing units per milliliter) on Gli36dEGFR cells by infecting confluent monolayers in 24-well plates (Falcon, Becton Dickinson GmbH, Heidelberg, Germany) and counting GFP-positive cells 24 h after infection (7) . Concentrated virus stocks (1 Â 10 8 transducing units/mL) were stored at À80jC for further use.
Transduction of tumor cell lines. To generate positive control tumors, a retroviral vector encoding the CITG coexpression construct was engineered in the pBABEpuro Moloney murine leukemia virus-based vector backbone (kind gift of Dr. Miguel Sena-Esteves, Neurogenetics Unit, 18 F]FLT-PET was done on subsequent days. White arrow, site of the transaxial slice depicted at the bottom (A). In the two small tumors, homogeneous radiotracer uptake is observed. In the medium-sized tumor on the animal's right shoulder, heterogeneous radiotracer uptake is observed. In the large tumor, no radiotracer uptake occurs in the central part of the tumor as indication of necrosis. The whole-body images also clearly depict the mode of excretion of the respective radiotracer: FDG Massachusetts General Hospital, Boston, MA) as previously described (7), including an exchange of the puromycin to the neomycin resistance gene. Thereafter, Gli36dEGFR cells were exposed to retrovirus-containing medium in the presence of polybrene (8 Ag/mL) for 8 h. GFP-positive Gli36dEGFR-CITG cells were selected under the presence of 1 mg/mL neomycin for 4 weeks. To generate a tumor clone with a defined level of CITG expression, the mixed cell population was sorted by means of fluorescence-activated cell sorting on a FACStar+ (Becton Dickinson). A Gli36dEGFR-CITG clone with high level of GFP expression was propagated for further use.
Animal experiments. All animal procedures were in accordance with the German Laws for Animal Protection and were approved by the local animal care committee and the Bezirksregierung Köln.
Identification and characterization of target tissue by multitracer PET. In a first set of experiments, various glioma cell lines (rat F98 and RG2 glioma, human Gli36dEGFR and U87dEGFR glioma) were implanted s.c. into nude rats (n = 12) and nude mice (n = 8) creating three to four tumors per animal, as previously described (7), to establish the noninvasive identification of target tissue. Tumors were grown to various sizes and multitracer PET imaging [2- Volumetry. Tumor sizes were measured twice a week with calipers. For each tumor, a growth curve was fitted and its slope calculated using linear regression analysis. Growth slopes of in vivo transduced tumors and of positive control tumors were related to slopes of respective negative controls intraindividually. A ratio between in vivo transduced tumor and negative controls of <1 indicated a decelerated growth of transduced tumor and thus a response to therapy. Tumors responding to therapy were further classified as complete responders (tumor disappeared completely) and partial responders (decelerated growth).
Radiosyntheses. [ Ten milligrams of precursor dissolved in 0.8-mL DMSO were added to the residue and heated to 160jC for 10 min. The hydrolysis was followed with the addition of 0.3-mL 1 N HCl under 130jC for 5 min. After cooling to 30jC, 0.5-mL 0.5 N Na 2 CO 3 was added to the reaction solution, which was first passed through a Sep-Pak cartridge (Al-N) to remove kryptofix 2.2.2 and unreacted fluoride, and the Sep-Pak was washed with 0.5-mL high-performance liquid chromatography solvent (10% ethanol in water). Finally, the effluent was automatically injected onto a semipreparative column [synthesis module: Phenomenex Luna C-18(2) 5 Am, 250 Â 10 mm; precolumn: Phenomenex Luna C-18(2) 5 Am, 50 Â 10 mm] for highperformance liquid chromatography purification. The no-carrier-added 18 F]FHBG (7) were produced as previously described. Multimodal imaging. T 1 -weighted magnetic resonance images for localization of tumors were obtained in the second set of experimental animals (n = 22 nude mice) on a 1.5-T Philips Gyroscan Intera before in vivo transduction. PET imaging was done in all animals from both sets of experiments using either a high-resolution research tomograph (ECAT HRRT, CTI/Siemens PET Systems, Knoxville, TN; 207 image planes; spatial resolution of 2.0-mm full width at the half maximum at the center of the field of view) or a microPET (Concorde Microsystems, Inc., Knoxville, TN; 63 image planes; 2.0-mm full width at the half maximum placed within the field of view of the PET scanner. To allow image coregistration, a newly developed software was used allowing for fast automated coregistration of multimodal imaging data as previously described (VINCI; ref. 25) . Data evaluation was based on a region of interest analysis of PET images to determine maximal radioactivity concentrations within tumors. After background (mediastinum) subtraction, data were decay corrected and divided by the total injected dose to represent percentage injected dose per gram (%ID/g).
As gene therapy vectors have to be applied into viable tumor tissue to ensure expression of therapeutic genes, a protocol for acquisition of a series of multimodal images was established, which allows identification of viable target tissue before the initiation of gene therapy using [ Tissue sampling and histology. After the last PET measurements, animals were killed and s.c. tumors were extracted rapidly. After fixation (4% paraformaldehyde, 4jC, 24 h), tumors were embedded in tissue-freezing medium (Jung, Nussloch, Germany) and 20-Am frozen sections were prepared along the transaxial plane relative to the tumor position in the animal. H&E staining on the tissue was done according to standard protocols. Image validation on tumor tissue sections, which has been transduced by tkgfp-expressing HSV-1 amplicon vectors, has been done as previously described (7, 28) .
Statistics. Descriptive statistics and regression analysis were done with Microsoft Excel 2002 (Microsoft Corp., Redmond, WA). Student's t test was done with SigmaStat 3.0 (SPSS, Inc., Chicago, IL); statistical significance was set at P < 0.05.
Results
Identification of target tissue for gene therapy is possible by multitracer PET. To validate the feasibility of PET for the identification of viable target tissue, which would be amenable for the local application of gene therapy vectors, in the first set of experiments, tumors growing s.c. in nude rats (n = 12) and nude mice (n = 8) were visualized by multitracer PET and assessed with respect to the different characteristics of radiotracer uptake within the tumor. Three radiotracers were used, of which two have routine clinical application in patients with gliomas ( (Fig. 1A) . In the latter, no radiotracer uptake occurred in the central part of the tumors indicative of central necrosis. For image validation, transaxial PET images were coregistered with histology showing a correlation between the lack of tracer accumulation and the histologic signs of necrosis, whereas positive tracer accumulation correlated with viable tumor tissue (Fig. 1B) . Radiotracer distribution in viable tumor tissue and necrosis for the different tumor types and in various organs are depicted in Table 1 . Tumor-to-background ratios ranged from 18 F]FLT showed substantial uptake in kidney and bladder, and [ 11 C]MET accumulation was highest in the liver (Fig. 1A) .
Imaging-guided vector application is feasible. To enable targeted application of vector particles into viable tumor tissue, image-guided vector application was done as depicted in Fig. 2A with (i) magnetic resonance imaging (MRI) for localization of tumor; (ii) [ (Fig. 2B) .
The outcome as measured by tumor volume showed 50% partial and 18% complete responses. To assess the gene therapeutic effect by standard volumetric assay, 22 nude mice with human Gli36dEGFR gliomas were transduced in vivo with HSV-1-cdIREStk39gfp amplicon vectors and subjected to prodrug therapy with ganciclovir and 5-fluorocytosine. Growth slopes of tumors were determined and used to assess response to therapy (Fig. 3A) . All 22 positive control tumors stably expressing cd and tk39gfp were successfully treated with prodrugs leading to disappearance of tumors within 10 days (Fig. 3B) . Of 22 in vivo transduced tumors, 4 tumors disappeared completely during prodrug therapy (complete responders). Eleven other in vivo transduced tumors showed a decelerated growth compared with the negative control tumors in the respective same animals (partial responders, growth of 28 F 16% compared with negative controls). This represents a response rate of 15 of 22 (68%) in vivo transduced tumors (Fig. 3B) . Growth slopes of tumors responding to gene therapy differed significantly from those of negative control tumors (t test, P < 0.05). Seven of 22 in vivo transduced tumors did not respond to prodrug therapy.
[ 18 F]FLT-PET is able to assess tumor response after 1 week of prodrug therapy. To assess the effects of gene therapy on tumor proliferation, [ (Fig. 6C) . Figure 6C also indicates a positive relation between the change in FLT uptake and volumetry in nonresponding tumors (R = 0.57). It should be pointed out that 22 mice have been studied in the same study protocol. Volumetric data were obtained in all animals; the full set of imaging data could only be obtained in 11 of these 22 animals. The correlations between FLT-PET and FHBG-PET (Fig. 6B) , as well as between FLT-PET and volumetry (Fig. 6C) , are based on these 11 animals.
Discussion
Gene therapy is one of the promising approaches for a targeted treatment of tumors. However, its efficiency in clinical application for patients with glioblastomas has been disappointing thus far and reported to occur only in small tumors. The most important hurdles for successful application of gene therapy in patients with glioblastomas are the heterogeneity of tumor tissue and the limited transduction efficiency of current vectors. In this study, we therefore aimed at the further characterization of these two limiting factors by (i) identification of viable target tissue that might benefit from gene therapy and (ii) quantification of the transduction efficiency, both assessed noninvasively by PET. The imaging protocol used was aimed to reflect the procedures that would be done in a clinical situation. First, MRI was used for exact tumor localization. Then, markers for endogenous gene expression, such as FDG and FLT for the expression of glucose and nucleoside transporters, as well as for the expression of cellular hexokinase and thymidine kinase genes, respectively, and MET for the expression of amino acid transporters, were used to identify the actively proliferating tumor tissue. In addition, these tracers can be used as surrogate markers for cellular density (FDG), neovascularization (MET), and proliferative activity (FLT). FLT was also used to determine the gene therapy-induced inhibition of proliferative activity of the tumor. A marker for exogenously introduced therapeutic gene expression (FHBG) could localize the transduced tissue dose of therapeutic gene expression. Using this ''imagingguided'' gene therapy protocol, we found a response rate of 68% of the in vivo transduced tumors with 18% complete responders as deduced from tumor volumetry. Most importantly, the primary transduction efficiency as measured by FHBG-PET could be correlated with the induced therapeutic effect, although followup imaging data by use of FLT-PET could only be obtained in 50% of investigated animals due to the complexity of the protocol. In tumors that responded to therapy, the decrease in FLT uptake corresponded to the decrease in tumor volume.
Several clinical gene therapy trials have outlined the promises as well as the difficulties associated with gene therapy. Suicide gene therapy for patients with recurrent glioblastoma using the HSV-1-TK/ganciclovir system has been done using retroviral (11, 14) , adenoviral (29, 30) , and HSV-1 (10, 13) vectors. Usually, imaging follow-up in those studies is done by gadolinium-enhanced MRI bearing the difficulty of assessing residual active tumor tissue after therapy and differentiating it from treatment-induced enhancement. Overall, it has been shown that suicide gene therapy has potential therapeutic efficacy, which nevertheless remains either partial or occurs only in single patients with small tumors. Explanations for the limited therapeutic efficiency include the heterogeneity of target tissue (31) , insufficient transduction efficiency (32) , and interindividual variability of infectivity by vector particles due to different entry receptor status (8) . Ongoing research focuses on the development of safe replication-conditional vectors and genetic approaches to target vascular and growth factor receptors and transforming growth factor-h, as well as to stimulate the immune response. All of these approaches rely on the noninvasive visualization of the target to allow an efficient targeted application of vectors and therapeutic genetic material and to allow a direct assessment of efficiency (15) .
Some authors have reported noninvasive imaging follow-up of suicide gene therapy in experimental models, but these studies were usually done on tumors grown from stably transfected cell lines (33) (34) (35) (36) . Few studies used molecular imaging-guided followup after transduction of therapeutic genes in vivo using adenoviral (37, 38) and lentiviral vectors (39) . To our knowledge, this is the first study of a HSV-1 amplicon vector-mediated gene therapy approach that uses multimodal molecular imaging techniques for noninvasive follow-up in a glioma model.
HSV-1 has many properties that make it especially suitable as a vector to treat diseases affecting the CNS (i.e., its natural neurotropism, high transduction efficiency, large transgene capacity, and the ability of entering a latent state in neurons). Besides replicationconditional HSV-1 mutants, the ''gutless'' HSV-1 amplicon vector has several properties, which make it a promising candidate gene transfer vehicle for clinical use (6, 40) . No virus proteins are encoded; it is nearly nontoxic when packaged without contaminating helper virus; and it can infect most mammalian cell types and can accommodate large fragments of foreign DNA. Helper virus-free packaging systems use replication-competent, packaging-defective genomes of HSV-1 to provide the functions necessary for replication and packaging of cotransfected amplicon DNA (5, 41, 42) . The resulting stocks of helper virus-free HSV-1 amplicons have been shown to be safe and efficient in culture and in vivo, and they transduce a variety of CNS-derived cells including human gliomas (4, 6, 7, 43, 44) . Moreover, we have shown that vector-mediated gene expression mediated by replication-conditional and HSV-1 amplicon vectors can be noninvasively assessed in vivo by PET (7, 28) .
Noninvasive localization of exogenously introduced gene expression by PET relies on the transduction of ''marker genes'' along with the therapeutic genes. Radiolabeled 9-(4- to detect HSV-1-tk expression (26, 45 F]FLT accumulation after and before therapy. C, relation between changes in volumetry and FLT uptake. Changes in tumor volume and FLT uptake were plotted for all tumors grown in 11 animals where the full imaging protocol could be completed. There is a strong correlation between volumetry and change in FLT uptake (R = 0.83) for those tumors responding to therapy (complete responders) and a weaker correlation (R = 0.57) for those tumors not responding to therapy (nonresponders). No correlation was found for those tumors where focal alterations of FLT uptake occurred, which did not lead to a reduction in overall tumor volume (partial responders). mutated thymidine kinase HSV-1-tk39 (7, 46) to serve as a PET marker gene and as a therapeutic gene at the same time.
To enhance the antitumoral effects of our construct, we used two therapeutic genes, Escherichia coli cd and HSV-1-tk39, which confer sensitivity to the prodrugs 5-fluorocytosine and ganciclovir, respectively. TK39 phosphorylates the nontoxic prodrug ganciclovir, which then becomes phosphorylated by endogenous kinases to ganciclovir-triphosphate, causing chain termination and singlestrand breaks on incorporation into DNA (47). Moreover, not only cells expressing the transgene but also neighboring nontransduced tumor cells can undergo cell death by bystander killing (48) . CD deaminates the nontoxic pyrimidine 5-fluorocytosine to the cytotoxic 5-fluorouracil (5-FU). 5-FU is processed both to the ribonucleotide 5-fluorouracil triphosphate, which is incorporated into RNA and interferes with RNA processing, and to 5-fluoro-2-deoxyuridine-5-monophosphate, which irreversibly inhibits thymidylate synthase and interferes with DNA synthesis (49) . TK/ ganciclovir-and CD/5-fluorocytosine-induced apoptoses converge at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins (50). The combination of those two therapeutic genes has been shown to have synergistic effects in glioma cells (20, 51, 52) , although Moriuchi et al. (53) critically proposed a mutual counteractivity. Previously, we have shown for our cdIREStk39gfp construct a proportional coexpression of cd and tk39gfp and did not observe an attenuation of the killing of glioma cells for this combination (7) .
To localize and distinguish the viable tissue of the tumors and to observe their response to therapy, the clinical PET marker for tumor proliferation, [ 18 F]FLT, was used. [ (59) (60) (61) . [ 18 F]FLT is especially suitable for therapy follow-up, as it reflects early effects of anticancer therapy (62) . In tumors that responded to gene therapy, we found [ 18 F]FLT accumulation to decrease already within a few days after initiation of prodrug application (Figs. 4-6) . A corresponding reduction in tumor volume was found (Fig. 6C) . It should be pointed out that [ 18 F]FLT-PET revealed additional, complementary information about tumor progression than volumetry. Some tumors that increased in volume during the course of treatment showed decreasing proliferation as measured by [ 18 F]FLT accumulation in follow-up studies. This decreased proliferative activity was always observed in the part of the glioma where in vivo transduction had taken place, which was visualized as HSV-1-tk39 expression by [ 18 F]FHBG-PET, whereas the rim of the tumor usually showed a higher proliferative activity (Fig. 5) Because we used a replication-deficient amplicon vector that could transduce tumor cells only at the injection site, the therapeutic response in larger tumors was therefore restricted to that injection site also. Thus, the transduced therapeutic gene caused a local regression of tumor proliferation, which was not sufficient to stop proliferation of the entire tumor. These findings are supported by the correlation between level of CD-IRES-TK39-GFP expression as measured by [ 18 F]FHBG-PET and therapeutic efficiency as measured by [ 18 F]FLT-PET (Fig. 6B) . In summary, we conclude that the identification of target tissue enables targeted vector application, which will be an essential tool in clinical applications. Determination of the tissue dose of vectormediated gene expression is feasible and enables a correlation to the induced therapeutic effect. This type of multimodal imaging protocol, together with improved vector and promoter technology (63, 64) for tumor-specific targeting, will be of great importance for the further development of clinical gene therapy trials, as an ineffective transduction and low tissue dose of therapeutic gene can be noted early, which may guide the further management of the patient to avoid that he is treated in vain. This type of imagingguided gene therapy protocol will therefore facilitate the development of safe and efficient gene therapy protocols for clinical application.
